DESCRIPTION

• Notes: To generate a VSIG4 stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve, https://bpsbioscience.com/cell-line-faq), for antibiotic selection of transduced cells, followed by clonal selection. Biosafety: The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email support@bpsbioscience.com.
• Shiptemp: -80°C (dry ice)
• Warnings: Avoid freeze/thaw cycles
• Category: Cancer Therapy Target/Lentivirus
• Background: VSIG4 also known as V-set and immunoglobulin domain containing 4, is an immunoglobulin of the B7 family of immune regulatory proteins. VSIG4 contributes to immune homeostasis by multiple mechanisms. It is a receptor for the complement component 3 fragment C3b and iC3b, where binding triggers receptor internalization and promotes inflammation. While most of the B7 homologues are expressed at low levels in resting cells, VSIG4 is abundantly expressed in non-active peripheral tissues macrophages and downregulated when cells become activated and is hardly found in lymphoid tissue macrophages. VSIG4 has been identified as an inhibitor of T cell responses as effectively as PD-L1 (programmed death-ligand 1), inhibiting T cell proliferation and contributing to cancer progression. Similarly to PD-L1, VSIG4 can be considered an immune checkpoint and be an attractive target in cancer therapy.
• References: Vogt L., et al., 2006 J Clin Invest. 116(10): 2817-26.Liu B., et al., 2023 Cancer Lett. 553: 215996.
• Description: VSIG4 (V-set and immunoglobulin domain containing 4) Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles contain human VSIG4 (NM_007268.3) driven by a CMV promoter and a puromycin selection marker.
• Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
• Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Applications: • Expression of human VSIG4 in cells of interest. • Generate cell pools or stable cell lines expressing human VSIG4 following puromycin selection.
• Product Type: Lentivirus
• Biosafety Level: BSL-2
• Related Products: 79491, 100044, 100349
• Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw.
• Scientific Category: Cancer Therapy Target